ABSTRACT
Objective: To determine the presence of antimyloperoxidase [anti-MPO] in rheumatoid arthritis patients in order to assess its relation to disease pattern
Methodology: Serum antimyeloperoxidase antibodies were assessed with Enzyme Linked Immunosorbent Assay [ELISA] in 25 rheumatoid arthritis patients and 10 controls
Results: Anti-MPO was found in 60% of patients and 10% of controls with a high statistical difference between the patients and control groups [p > 0. 001]. Also there was a highly significant difference between the patients and controls regarding ESR [p < 0.001] and serum creatinine [p< 0.05]. There was no correlation between the mean anti-MPO and activity sore, duration of morning stuffiness and number of affected joints [p> 0.05]. There was a positive correlation between serum creatinine duration of RA, ESR and disease severity with mean of Anti-MPO among cases [p<0.01]
Conclusion: The use of Anti-MPO helps in the assessment of RA disease activity and help in the assessment of disease severity and prediction of renal affection. It cannot be used to predict the onset of RA but can be used as an indicator of long standing RA disease